ArticleNature communications2025
USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Reprogramming of cell death in gastric cancer: From molecular mechanisms to therapeutic potential (Review).International journal of molecular medicine · 2026Review
- Mechanisms underlying propagation of ferroptotic cell death.Nature cell biology · 2026Review
- PCK2 Inhibition Reverses Cisplatin Resistance of Non-Small Cell Lung Cancer by Triggering Ferroptosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Carrier-Free Berberine/Nitidine Chloride Self-Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.Cancer science · 2026Article
- Protein Post-Translational Modifications in the Regulation of Ferroptosis: New Opportunities and Challenges for Cancer Immunotherapy.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gastric cancer (GC) ranks as the third leading cause of cancer-related mortality. Chemoresistance poses a major obstacle to successful treatment for GC patients. Here, we demonstrate that ferroptosis suppressor protein 1 (FSP1) enables chemoresistance in GC by inhibiting ferroptosis, resulting in diminished chemotherapy response and reduced patient survival rate. USP29 and SMURF1 are subsequently discovered as the deubiquitinase and E3 ligase of FSP1, respectively, orchestrating the ubiquitination of FSP1 to modulate ferroptosis and chemoresistance in GC. In the ubiquitination process, SMURF1 is observed to interact with and polyubiquitinate FSP1 within K63/K193 sites. Notably, pharmacological inhibition of FSP1 by iFSP1 is shown to synergize with chemotherapeutic agents across chemoresistant cellular and mouse models. Our findings thus underscore the pivotal role of the USP29 and SMURF1 in regulating GC chemoresistance via FSP1-mediated ferroptosis suppression. FSP1 inhibition may represent a promising therapeutic avenue to overcome chemoresistance in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.